InMode Ltd. has confirmed receipt of an unsolicited acquisition proposal at $16.20 per share from a CEO-led group. The proposal values the company at approximately $1.1 billion and represents a significant premium to recent trading levels, signaling strong strategic interest in InMode's RF microneedling and energy-device portfolio.
InMode's core platforms—Morpheus8 (fractional RF microneedling), Lumenis IPL, and Evolve (radiofrequency body contouring)—are among the highest-revenue-per-unit energy devices in the medspa market. The company has built a strong direct-to-practice sales model and loyalty program, and its devices command premium pricing due to clinical efficacy and brand recognition. A takeout at this valuation reflects PE appetite for consolidation in the energy-device space, where margins remain attractive and recurring revenue from handpiece sales is predictable.